The leader of Europe’s defence industry published the final version of its results ahead of Thursday’s market open.
This situation shows how volatile market sentiment can be toward the company and, de facto, the entire sector. Preliminary results released earlier this week showed almost the same figures as the final report, yet the market reacted very differently to similar releases. In the afternoon, shares of the German company are down between 2% and 3%.
Financial metrics:
- Sales revenue increased to EUR 1.94bn, representing a 7.7% y/y rise.
- Operating profit rose to EUR 224m (+17% y/y), but still below the consensus of EUR 262m.
- FCF also came in above expectations, rising to EUR 285m versus expectations of EUR 181m.
- Operating margin increased to 11.6% compared with 10.6% a year ago.
- EPS came in at EUR 2.42 versus expectations of around EUR 2.70.
- Backlog increased by 30%, reaching a record EUR 73bn.
Despite strong growth, especially in profitability, investors reacted negatively to sales that came in clearly below expectations. The company disappointed, de facto, across the entire breadth of its operations. Market consensus had assumed sales revenue above EUR 2.1 - 2.2bn.
Company guidance:
Although the company reported sales and operating profit below expectations, management reassured investors on the conference call that the annual target of 40 - 45% sales growth remains valid.
Other highlights:
- Investors may welcome the ramp-up to full-scale production at the ammunition plant in Murcia.
- The market currently appears to pin meaningful near-term hopes on an increase in truck deliveries and the company’s significant expansion in the maritime segment.
- Management explained the weak sales and operating performance mainly by a high comparison base and the characteristics of the sales cycle.
- A series of internal transactions also stands out. Two key management board members, including the CEO, purchased shares with a combined value of nearly EUR 1m.
Conclusion:
Historically, the first quarters of the financial year have been the weakest for Rheinmetall. This does not reflect a lack of demand, but rather the scheduling of defence contracts. Record backlog alongside rising margins is a strong signal of improving efficiency and solid prospects - sales growth coming in below fairly elevated expectations is merely a single indicator of a temporary slowdown.
Insider transactions highlight this clearly. When analysing insider trading, it is worth remembering that there are many reasons to sell, but only one reason to buy shares.
RHM.DE (D1)
On the chart, the share price remains in the lower part of a long-term consolidation range. Historically, the price is close to zones and levels (especially RSI) where rebounds have occurred and the price has returned to the upper boundary of the range. From a technical perspective, closely monitoring the EMA100 and EMA200 will be key. Source: xStation5.
ARM Holdings Moves Closer to the Center of the AI Revolution. Strong Results Are No Longer Enough for the Market
Market wrap 🚨Oil slips below $100 supporting optimism across European and US stocks
Chart of the Day: EURUSD Higher, but Still a Game of Expectations, Not a Trend
NOK surges following Norges Bank's rate hike
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.